Structure-antiplatelet activity relationships of novel ruthenium (ii) complexes: Investigation of its molecular targets

Chih Hsuan Hsia, Thanasekaran Jayakumar, Joen Rong Sheu, Shin Yi Tsao, Marappan Velusamy, Chih Wei Hsia, Duen Suey Chou, Chao Chien Chang, Chi Li Chung, Themmila Khamrang, Kao Chang Lin

研究成果: 雜誌貢獻文章

2 引文 (Scopus)

摘要

The regulation of platelet function by pharmacological agents that modulate platelet signaling has proven to be a positive approach to the prevention of thrombosis. Ruthenium complexes are fascinating for the development of new drugs, as they possess numerous chemical and biological properties. The present study aims to evaluate the structure-activity relationship (SAR) of newly synthesized ruthenium (II) complexes, TQ-1, TQ-2 and TQ-3 in agonists-induced washed human platelets. Silica gel column chromatography, aggregometry, immunoblotting, NMR, and X-ray analyses were performed in this study. Of the three tested compounds, TQ-3 showed a concentration (1–5 µM) dependent inhibitory effect on platelet aggregation induced by collagen (1 µg/mL) and thrombin (0.01 U/mL) in washed human platelets; however, TQ-1 and TQ-2 had no response even at 250 µM of collagen and thrombin-induced aggregation. TQ-3 was effective with inhibiting collagen-induced ATP release, calcium mobilization ([Ca2+]i) and P-selectin expression without cytotoxicity. Moreover, TQ-3 significantly abolished collagen-induced Lyn-Fyn-Syk, Akt-JNK and p38 mitogen-activated protein kinases (p38 MAPKs) phosphorylation. The compound TQ-3 containing an electron donating amino group with two phenyl groups of the quinoline core could be accounted for by its hydrophobicity and this nature might be the reason for the noted antiplatelet effects of TQ-3. The present results provide a molecular basis for the inhibition by TQ-3 in collagen-induced platelet aggregation, through the suppression of multiple machineries of the signaling pathway. These results may suggest that TQ-3 can be considered a potential agent for the treatment of vascular diseases.
原文英語
文章編號477
期刊Molecules
23
發行號2
DOIs
出版狀態已發佈 - 二月 22 2018

指紋

Ruthenium
Structure-Activity Relationship
Platelets
platelets
ruthenium
collagens
Collagen
Blood Platelets
thrombin
Platelet Aggregation
Agglomeration
Thrombin
P-Selectin
JNK Mitogen-Activated Protein Kinases
thrombosis
Silica Gel
p38 Mitogen-Activated Protein Kinases
phosphorylation
Column chromatography
Phosphorylation

ASJC Scopus subject areas

  • Organic Chemistry

引用此文

Structure-antiplatelet activity relationships of novel ruthenium (ii) complexes : Investigation of its molecular targets. / Hsia, Chih Hsuan; Jayakumar, Thanasekaran; Sheu, Joen Rong; Tsao, Shin Yi; Velusamy, Marappan; Hsia, Chih Wei; Chou, Duen Suey; Chang, Chao Chien; Chung, Chi Li; Khamrang, Themmila; Lin, Kao Chang.

於: Molecules, 卷 23, 編號 2, 477, 22.02.2018.

研究成果: 雜誌貢獻文章

Hsia, Chih Hsuan ; Jayakumar, Thanasekaran ; Sheu, Joen Rong ; Tsao, Shin Yi ; Velusamy, Marappan ; Hsia, Chih Wei ; Chou, Duen Suey ; Chang, Chao Chien ; Chung, Chi Li ; Khamrang, Themmila ; Lin, Kao Chang. / Structure-antiplatelet activity relationships of novel ruthenium (ii) complexes : Investigation of its molecular targets. 於: Molecules. 2018 ; 卷 23, 編號 2.
@article{a3738626b1a84a308c194dfc001e2aa5,
title = "Structure-antiplatelet activity relationships of novel ruthenium (ii) complexes: Investigation of its molecular targets",
abstract = "The regulation of platelet function by pharmacological agents that modulate platelet signaling has proven to be a positive approach to the prevention of thrombosis. Ruthenium complexes are fascinating for the development of new drugs, as they possess numerous chemical and biological properties. The present study aims to evaluate the structure-activity relationship (SAR) of newly synthesized ruthenium (II) complexes, TQ-1, TQ-2 and TQ-3 in agonists-induced washed human platelets. Silica gel column chromatography, aggregometry, immunoblotting, NMR, and X-ray analyses were performed in this study. Of the three tested compounds, TQ-3 showed a concentration (1–5 µM) dependent inhibitory effect on platelet aggregation induced by collagen (1 µg/mL) and thrombin (0.01 U/mL) in washed human platelets; however, TQ-1 and TQ-2 had no response even at 250 µM of collagen and thrombin-induced aggregation. TQ-3 was effective with inhibiting collagen-induced ATP release, calcium mobilization ([Ca2+]i) and P-selectin expression without cytotoxicity. Moreover, TQ-3 significantly abolished collagen-induced Lyn-Fyn-Syk, Akt-JNK and p38 mitogen-activated protein kinases (p38 MAPKs) phosphorylation. The compound TQ-3 containing an electron donating amino group with two phenyl groups of the quinoline core could be accounted for by its hydrophobicity and this nature might be the reason for the noted antiplatelet effects of TQ-3. The present results provide a molecular basis for the inhibition by TQ-3 in collagen-induced platelet aggregation, through the suppression of multiple machineries of the signaling pathway. These results may suggest that TQ-3 can be considered a potential agent for the treatment of vascular diseases.",
keywords = "Akt-JNK-p38, ATP, Lyn-Fyn-Syk, Platelets, Ruthenium complexes, SAR, [Ca]i, Ruthenium Compounds/chemical synthesis, Phosphorylation, Humans, Structure-Activity Relationship, Thrombosis/drug therapy, Platelet Activation/drug effects, Ruthenium/chemistry, Platelet Aggregation Inhibitors/chemical synthesis, Platelet Aggregation/drug effects, Collagen/chemistry, Blood Platelets/drug effects",
author = "Hsia, {Chih Hsuan} and Thanasekaran Jayakumar and Sheu, {Joen Rong} and Tsao, {Shin Yi} and Marappan Velusamy and Hsia, {Chih Wei} and Chou, {Duen Suey} and Chang, {Chao Chien} and Chung, {Chi Li} and Themmila Khamrang and Lin, {Kao Chang}",
year = "2018",
month = "2",
day = "22",
doi = "10.3390/molecules23020477",
language = "English",
volume = "23",
journal = "Molecules",
issn = "1420-3049",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

TY - JOUR

T1 - Structure-antiplatelet activity relationships of novel ruthenium (ii) complexes

T2 - Investigation of its molecular targets

AU - Hsia, Chih Hsuan

AU - Jayakumar, Thanasekaran

AU - Sheu, Joen Rong

AU - Tsao, Shin Yi

AU - Velusamy, Marappan

AU - Hsia, Chih Wei

AU - Chou, Duen Suey

AU - Chang, Chao Chien

AU - Chung, Chi Li

AU - Khamrang, Themmila

AU - Lin, Kao Chang

PY - 2018/2/22

Y1 - 2018/2/22

N2 - The regulation of platelet function by pharmacological agents that modulate platelet signaling has proven to be a positive approach to the prevention of thrombosis. Ruthenium complexes are fascinating for the development of new drugs, as they possess numerous chemical and biological properties. The present study aims to evaluate the structure-activity relationship (SAR) of newly synthesized ruthenium (II) complexes, TQ-1, TQ-2 and TQ-3 in agonists-induced washed human platelets. Silica gel column chromatography, aggregometry, immunoblotting, NMR, and X-ray analyses were performed in this study. Of the three tested compounds, TQ-3 showed a concentration (1–5 µM) dependent inhibitory effect on platelet aggregation induced by collagen (1 µg/mL) and thrombin (0.01 U/mL) in washed human platelets; however, TQ-1 and TQ-2 had no response even at 250 µM of collagen and thrombin-induced aggregation. TQ-3 was effective with inhibiting collagen-induced ATP release, calcium mobilization ([Ca2+]i) and P-selectin expression without cytotoxicity. Moreover, TQ-3 significantly abolished collagen-induced Lyn-Fyn-Syk, Akt-JNK and p38 mitogen-activated protein kinases (p38 MAPKs) phosphorylation. The compound TQ-3 containing an electron donating amino group with two phenyl groups of the quinoline core could be accounted for by its hydrophobicity and this nature might be the reason for the noted antiplatelet effects of TQ-3. The present results provide a molecular basis for the inhibition by TQ-3 in collagen-induced platelet aggregation, through the suppression of multiple machineries of the signaling pathway. These results may suggest that TQ-3 can be considered a potential agent for the treatment of vascular diseases.

AB - The regulation of platelet function by pharmacological agents that modulate platelet signaling has proven to be a positive approach to the prevention of thrombosis. Ruthenium complexes are fascinating for the development of new drugs, as they possess numerous chemical and biological properties. The present study aims to evaluate the structure-activity relationship (SAR) of newly synthesized ruthenium (II) complexes, TQ-1, TQ-2 and TQ-3 in agonists-induced washed human platelets. Silica gel column chromatography, aggregometry, immunoblotting, NMR, and X-ray analyses were performed in this study. Of the three tested compounds, TQ-3 showed a concentration (1–5 µM) dependent inhibitory effect on platelet aggregation induced by collagen (1 µg/mL) and thrombin (0.01 U/mL) in washed human platelets; however, TQ-1 and TQ-2 had no response even at 250 µM of collagen and thrombin-induced aggregation. TQ-3 was effective with inhibiting collagen-induced ATP release, calcium mobilization ([Ca2+]i) and P-selectin expression without cytotoxicity. Moreover, TQ-3 significantly abolished collagen-induced Lyn-Fyn-Syk, Akt-JNK and p38 mitogen-activated protein kinases (p38 MAPKs) phosphorylation. The compound TQ-3 containing an electron donating amino group with two phenyl groups of the quinoline core could be accounted for by its hydrophobicity and this nature might be the reason for the noted antiplatelet effects of TQ-3. The present results provide a molecular basis for the inhibition by TQ-3 in collagen-induced platelet aggregation, through the suppression of multiple machineries of the signaling pathway. These results may suggest that TQ-3 can be considered a potential agent for the treatment of vascular diseases.

KW - Akt-JNK-p38

KW - ATP

KW - Lyn-Fyn-Syk

KW - Platelets

KW - Ruthenium complexes

KW - SAR

KW - [Ca]i

KW - Ruthenium Compounds/chemical synthesis

KW - Phosphorylation

KW - Humans

KW - Structure-Activity Relationship

KW - Thrombosis/drug therapy

KW - Platelet Activation/drug effects

KW - Ruthenium/chemistry

KW - Platelet Aggregation Inhibitors/chemical synthesis

KW - Platelet Aggregation/drug effects

KW - Collagen/chemistry

KW - Blood Platelets/drug effects

UR - http://www.scopus.com/inward/record.url?scp=85042400250&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042400250&partnerID=8YFLogxK

U2 - 10.3390/molecules23020477

DO - 10.3390/molecules23020477

M3 - Article

C2 - 29470443

AN - SCOPUS:85042400250

VL - 23

JO - Molecules

JF - Molecules

SN - 1420-3049

IS - 2

M1 - 477

ER -